Moderna Income Statement 2025-2011 | MRNA

Brief overview of financial results at Moderna

The figures are compared over a five-year interval. Revenue reported by Moderna was $803 million at the beginning of the period and $1.9 billion at the end. The cumulative result was +142.1%, corresponding to roughly 19.3% per year. The trajectory reflects meaningful expansion of the business.

The five-year change in gross profit reached +35.3%: from 795 million dollars to 1.1 billion dollars. The cost base moved against the top-line trend and weighed on the gross result. At the margin level, the figure shifted from 99% to 55.3%. The business retained less gross profit from each unit of revenue.

The operating result measured by EBITDA moved from −$732 million to −$2.9 billion, or −291.1%. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −91.2% to −147.3%. The business retained less EBITDA from each unit of revenue.

Net income moved from −747 million dollars at the start to −2.8 billion dollars at the end. The negative result deepened, showing weaker final efficiency.

Market capitalization changed from 59 billion dollars to 19.4 billion dollars (−67.1%). The market is not yet fully reflecting the fundamental progress.

Summary assessment

The indicators point to a weaker financial profile. The constructive conclusion rests on sales growth. The overall view is constrained by a weaker market valuation, limited operating profitability and declining net profitability. The key question is whether sales can be converted into sustainable profit.